公开(公告)号：US20170128541A1

公开(公告)日：2017-05-11

申请号：US15127512

申请日：2015-03-23

申请人： ANYGEN CO., LTD.

发明人： Jae Il KIM ,  San Ho KIM ,  Seon Myung KIM ,  Moon Young PARK

IPC分类号： A61K38/26 ,  A61K9/00

CPC分类号： A61K38/26 ,  A61K9/0053 ,  A61K38/00 ,  A61K47/542 ,  A61K47/61 ,  C07K14/605

摘要： The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.

公开(公告)号：US20180147182A1

公开(公告)日：2018-05-31

申请号：US15595164

申请日：2017-05-15

申请人： ANYGEN CO., LTD.

发明人： Jae il KIM ,  Seon-Myung KIM ,  San Ho KIM ,  Moon Young PARK

IPC分类号： A61K31/404 ,  C07D403/04 ,  A61K31/4155 ,  C07D209/38 ,  C12Q1/68

CPC分类号： A61K31/404 ,  A61K31/4155 ,  A61K45/06 ,  C07D209/38 ,  C07D403/04 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

摘要： A breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed.